Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs). The FDA ...

Analysts at ING have warned that the near-term result of pharma tariffs will be higher prices for medicines in the US, particularly generics, and could lead to access issues as, for some low ...